Dress for Success: Panel Mulls Best Early Stage Deal Chances
BOSTON – Even with a solid strategic fit, quality assets on the table and the likelihood of reimbursement by payers, intellectual property (IP) glitches can hurt a deal, warned Sanjeev Munshi, director of worldwide licensing and acquisition for Merck & Co. Inc.
Munshi’s remarks came during a panel talk called “How to Position Your Early Stage Company for Success” at Biopharm America, a three-day event focused on partnering.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter